Publications
420 results found
Gan A, Naresh K, Diamond E, et al., 2019, Two cellular populations occurring simultaneously in a patient with recurrent self-resolving skin lesions: Indeterminate cell histiocytosis and a previously undescribed population of small eosinophilic cells, 16th International Workshop on Langerhans Cells (LC), Publisher: WILEY, Pages: 16-16, ISSN: 0014-2980
Hanley B, Nesr G, Yebra-Fernandez E, et al., 2019, T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report, JOURNAL OF CLINICAL PATHOLOGY, Vol: 72, Pages: 511-512, ISSN: 0021-9746
Xu D, Claudiani S, Naresh K, et al., 2019, Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1., Leuk Lymphoma, Pages: 1-2
Korfi K, Araf S, BewickeCopley F, et al., 2019, LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA, Hematological Oncology, Vol: 37, Pages: 142-143, ISSN: 0278-0232
ElSharkawi D, Sharma S, Cook L, et al., 2019, COMPARISON OF OUTCOMES BETWEEN PATIENTS WITH <i>MYC</i> REARRANGED DLBCL AND DOUBLE/ TRIPLE HIT HIGH‐GRADE B CELL LYMPHOMA: A PAN‐LONDON RETROSPECTIVE REVIEW, Hematological Oncology, Vol: 37, Pages: 348-349, ISSN: 0278-0232
Granai M, Ambrosio MR, Akarca A, et al., 2019, Role of Epstein-Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature, HAEMATOLOGICA, Vol: 104, Pages: E269-E273, ISSN: 0390-6078
- Author Web Link
- Cite
- Citations: 12
Lo Bello G, Naresh KN, 2019, HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 185, Pages: 328-330, ISSN: 0007-1048
Webster P, Dawes JC, Dewchand H, et al., 2019, Subclonal mutation selection in mouse lymphomagenesis identifies known cancer loci and suggests novel candidates (vol 9, 2649, 2018), NATURE COMMUNICATIONS, Vol: 10, ISSN: 2041-1723
Ambrosio MR, Lazzi S, Lo Bello G, et al., 2019, MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients, HAEMATOLOGICA, Vol: 104, Pages: E25-E28, ISSN: 0390-6078
- Author Web Link
- Cite
- Citations: 22
Hanley BP, Yebra-Fernandez E, Palanicawandar R, et al., 2018, Lineage switch from acute myeloid leukemia to T cell/myeloid mixed phenotype acute leukemia: First report of an adult case, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 93, Pages: E395-E397, ISSN: 0361-8609
- Author Web Link
- Cite
- Citations: 7
Khorashad JS, Fiol CR, Yebra-Fernandez E, et al., 2018, "Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets, 60th Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
Rotolo A, Caputo VS, Holubova M, et al., 2018, Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting, Cancer Cell, Vol: 34, Pages: 596-610.e11, ISSN: 1535-6108
Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19+ B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19+ chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.
Elshiekh M, Naresh KN, 2018, A rare case of renal intravascular NK/T-cell lymphoma, BLOOD, Vol: 132, Pages: 1354-1354, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 7
Kousios A, Brah T, Troy-Barnes E, et al., 2018, The Histopathological Spectrum of Monoclonal Gammopathies of Renal Significance: A Single Centre Experience, 11th Joint Meeting of the British-Division of the International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland, Publisher: WILEY, Pages: S19-S19, ISSN: 0022-3417
Elshiekh M, Arora I, Du Parcq P, et al., 2018, Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung; a case report, Publisher: SPRINGER, Pages: S115-S115, ISSN: 0945-6317
Elshiekh M, Trivedi P, Roufosse C, et al., 2018, Renal intravascular NK/T cell lymphoma; a case report, Publisher: SPRINGER, Pages: S266-S266, ISSN: 0945-6317
Roufosse C, Brah T, Troy-Barnes E, et al., 2018, The histopathological spectrum of monoclonal gammopathies of renal significance: a single centre experience, Publisher: SPRINGER, Pages: S81-S81, ISSN: 0945-6317
Naresh KN, 2018, Genetics of Diffuse Large B-Cell Lymphoma, NEW ENGLAND JOURNAL OF MEDICINE, Vol: 379, Pages: 493-493, ISSN: 0028-4793
Webster P, Dawes J, Dewchand H, et al., 2018, Subclonal mutation selection in mouse lymphomagenesis identifies known cancer loci and suggests novel candidates, Nature Communications, Vol: 9, ISSN: 2041-1723
Determining whether recurrent but rare cancer mutations are bona fide driver mutationsremains a bottleneck in cancer research. Here we present the most comprehensiveanalysis of retrovirus driven lymphomagenesis produced to date, sequencing 700,000mutations from >500 malignancies collected at time points throughout tumordevelopment. This scale of data allows novel, novel statistical approaches for identifyingdriver mutations and yields a high-resolution, genome wide map of the selective forcessurrounding cancer gene loci. We also demonstrate negative selection of mutations thatmay be deleterious to tumor development indicating novel avenues for therapy.Screening two BCL2 transgenic models confirms known drivers of human B-cell non-Hodgkin lymphoma, and implicates novel candidates including modifiers ofimmunosurveillance and MHC loci. Correlating mutations with genotypic and phenotypicfeatures also gives robust identification of known cancer genes independently of localvariance in mutation density. An online resource http://mulv.lms.mrc.ac.uk allowscustomized queries of the entire dataset.
Elshiekh M, Naresh KN, 2018, Lymphoproliferative disorders and lymphoreticular malignancies in the setting of immunodeficiency, Diagnostic Histopathology, Vol: 24, Pages: 246-256, ISSN: 1756-2317
Lymphoid proliferations occurring in the background of immunodeficiency range from benign lymphoid proliferations to full-blown lymphomas. They occur at a higher frequency in immunosuppressed patients compared to the general population. Immunosuppression is the main underlying pathogenic cause in these disorders and their histological appearances and immunophenotypic features are varied. Some resemble lymphoproliferative disorders seen in immune competent patients whilst others have unique characteristics; some of these also pose unique diagnostic problems. Furthermore, within some clinical contexts like the post-transplant setting, the distinction between benign and malignant proliferations is blurred. Identification of specific entities requires a clear understanding of morphology, clinical context, a wide immunohistochemistry panel, investigations for viral association, clonality investigations, and in some situations analysis of chromosomal translocations by fluorescent in-situ hybridisation studies. Precise identification of the disease entity impacts patient management and follow-up.
Amen F, Eden M, Marker A, et al., 2018, Molecular prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas., Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Menter T, Medani H, Olavarria E, et al., 2018, Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 180, Pages: 904-908, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 1
Menter T, Abdulsalam AH, Nadal-Melsio E, et al., 2017, Correlation of multiparameter flow cytometry and bone marrow trephine immunohistochemistry in the identification and characterization of neoplastic plasma cells, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 179, Pages: 499-501, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 2
Menter T, Medani H, Ahmad R, et al., 2017, MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 179, Pages: 681-684, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 6
Munonyara M, Ramakrishnan R, Naresh K, et al., 2017, Multifocal extranodal Rosai-Dorfman disease affecting the cavernous sinuses and the skin - a case report, Publisher: SPRINGER, Pages: S157-S157, ISSN: 0945-6317
Menter T, Juskevicius D, Alikian M, et al., 2017, Mutational landscape of B-cell post-transplant lymphoproliferative disorders, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 178, Pages: 48-56, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 50
Webster P, Dawes JC, Dewchand H, et al., 2017, Tracking Subclonal Mutation Frequencies Throughout Lymphomagenesis Identifies Cancer Drivers in Mouse Models of Lymphoma
<jats:title>ABSTRACT</jats:title><jats:p>Determining whether recurrent but rare cancer mutations are bona fide driver mutations remains a bottleneck in cancer research. Here we present the most comprehensive analysis of retrovirus driven lymphomagenesis produced to date, sequencing 700,000 mutations from >500 malignancies collected at time points throughout tumor development. This enabled identification of positively selected events, and the first demonstration of negative selection of mutations that may be deleterious to tumor development indicating novel avenues for therapy. Customized sequencing and bioinformatics methodologies were developed to quantify subclonal mutations in both premalignant and malignant tissue, greatly expanding the statistical power for identifying driver mutations and yielding a high-resolution, genome wide map of the selective forces surrounding cancer gene loci. Screening two BCL2 transgenic models confirms known drivers of human B-cell non-Hodgkin lymphoma, and implicates novel candidates including modifiers of immunosurveillance such as co-stimulatory molecules and MHC loci. Correlating mutations with genotypic and phenotypic features also gives robust identification of known cancer genes independently of local variance in mutation density. An online resource <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://mulv.lms.mrc.ac.uk">http://mulv.lms.mrc.ac.uk</jats:ext-link> allows customized queries of the entire dataset.</jats:p>
Moffitt AB, Ondrejka SL, McKinney M, et al., 2017, Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2, JOURNAL OF EXPERIMENTAL MEDICINE, Vol: 214, Pages: 1371-1386, ISSN: 0022-1007
- Author Web Link
- Cite
- Citations: 104
Dalla Pria A, Pinato D, Roe J, et al., 2017, Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients, BLOOD, Vol: 129, Pages: 2143-2147, ISSN: 0006-4971
Successful treatment of HIV-associated multicentric Castleman disease (HIV+MCD) with rituximab-based approaches has dramatically improved survival and reduced the risk of human herpesvirus 8 (HHV8)-associated lymphoma. Longer term outcomes including relapse rates have not been described and are important to establish the potential role of maintenance therapy. A prospective cohort of 84 patients with biopsy-proven HIV+MCD were treated with risk-stratified rituximab-based therapy. Four patients (5%) died of refractory HIV+MCD and 80 achieved clinical remission. The median follow-up for the 80 patients was 6.9 years and their 5-year overall survival was 92% (95% confidence interval [CI], 85 to 99). Eighteen have relapsed (all histologically confirmed), including 5 with concomitant HHV8-associated lymphoma and MCD at relapse. The 5-year relapse-free survival is 82% (95% CI, 72 to 92). No clinical or laboratory findings that were present at MCD diagnosis predicted subsequent relapse, and the median time to first relapse was 30 months (maximum, 10 years). There were no significant differences in clinicopathological features at initial diagnosis and at relapse. All patients were successfully retreated at relapse with rituximab-based therapy. Only 1 patient died of relapsed MCD (at fifth relapse 9.4 years after initial diagnosis). Despite the use of rituximab, the risk of developing HHV8-associated lymphoma was significantly elevated in this cohort, with an incidence of 11.4/1000 person-years. The relatively low relapse rate and high salvage rates at relapse reduce the potential benefit of maintenance therapy; this should only be advocated in the context of a clinical trial.
Menter T, Trivedi P, Ahmad R, et al., 2017, Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, Vol: 147, Pages: 292-300, ISSN: 0002-9173
- Author Web Link
- Cite
- Citations: 15
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.